Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma

• Published in: OncoTargets and therapy 2017-01, Vol.10, p.5745-5754
• Main Authors: Qi, Xinmeng, Jia, Bo, Zhao, Xue, Yu, Dan
• Format: Article
• Language: English
• Subjects: Antigens; Apoptosis; Cancer immunotherapy; Cancer research; Cancer therapies; Care and treatment; Chemotherapy; Cytokines; Cytotoxicity; Epidermal growth factor; Head & neck cancer; Head and neck cancer; Health aspects; Homeostasis; Immune checkpoint; Immune system; Immunotherapy; Kidney cancer; Ligands; Lymphatic system; Medical prognosis; Melanoma; Metastasis; Otolaryngology; PD-1 protein; PD-L1 protein; Review; Squamous cell carcinoma; Surgery; T cells
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S148182

Head and neck squamous cell carcinoma (HNSCC) has been found to be a complex group of malignancies characterized by their profound immunosuppression and high aggressiveness. In most cases of advanced HNSCC, treatment fails to obtain total cancer cure. Efforts are needed to develop new therapeutic approaches to improve HNSCC outcomes. In this light, T-cells "immune checkpoint" has attracted much attention in cancer immunotherapy. It has been broadly accepted that inhibitory T-cell immune checkpoints contribute to tumor immune escape through negative immune regulatory signals (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], programmed cell death 1 [PD-1], B7-H3, and B7-H4, etc). Current data suggest that PD-1 and CTLA-4 receptors can inhibit T-cell receptors and T-cell proliferation. Blockade of PD-1/PD-L1 and/or CTLA-4/CD28 pathways has shown promising tumor outcomes in clinical trials for advanced solid tumors like melanoma, renal cell cancer, and non-small cell lung cancer. The present review attempts to explore what is known about PD-1/PD-L1 and CTLA-4/CD28 pathways with a focus on HNSCC. We further discuss how these pathways can be manipulated with therapeutic intent.